Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment (Gc)
|ClinicalTrials.gov Identifier: NCT00650780|
Recruitment Status : Completed
First Posted : April 2, 2008
Last Update Posted : April 2, 2008
|Condition or disease|
|Vitamin D Status|
We suspect that the wide range of response is effected by other factors such as variation in Vitamin D binding protein (the major transporter of Vitamin D metabolites).
Gc, also known as Vitamin D binding protein (DBP), group specific component, or Gc globulin, is a 52-58 kDa multifunctional plasma protein, synthesized in the liver. The gene encoding for Gc is located on chromosome 4, and three common co-dominant alleles give rise to three phenotypes (Gc1s, Gc1f, and Gc2). Gc binds actin, recruits neutrophil leukocytes and converts into a macrophage- and osteoclast- activating factor. It also is the major transporter of Vitamin D and its' metabolites. Lauridsen et al. showed that Gc phenotype correlates with 25(OH)D levels in a group of postmenopausal women.
This study proposes that Gc phenotype accounts for some of the variation in response of 25(OH)D levels after treatment with oral Vitamin D.
|Study Type :||Observational|
|Actual Enrollment :||29 participants|
|Official Title:||Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||January 2008|
All of the subjects will have measurements of Gc concentration and phenotype
- Gc concentration and phenotype [ Time Frame: at 1st visit ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00650780
|United States, Nebraska|
|Omaha, Nebraska, United States, 68131|
|Principal Investigator:||Laura Armas, MD||Creighton University|